Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tricida Inc. TCDAQ

Consumer Cyclical
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic... see more

Recent & Breaking News (PINL:TCDAQ)

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.

Newsfile February 8, 2023

Tricida Announces Third Quarter 2022 Financial Results

Business Wire November 14, 2022

Tricida Provides Strategic Update

Business Wire November 2, 2022

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Business Wire October 24, 2022

Tricida Announces $125 Million Debt Facility with Hercules Capital

Business Wire October 19, 2022

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm

Business Wire October 13, 2022

TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Business Wire September 23, 2022

TRICIDIA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

PR Newswire September 9, 2022

Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 6, 2022

TRICIDA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Business Wire August 26, 2022

Tricida Announces Second Quarter 2022 Financial Results

Business Wire August 8, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.

Newsfile August 2, 2022

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

GlobeNewswire August 1, 2022

Tricida Announces Administrative Stop of the VALOR-CKD Trial

GlobeNewswire May 19, 2022

Tricida Announces First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Tuesday, May 10, 2022

GlobeNewswire May 3, 2022

Tricida to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 1, 2022

Tricida Announces Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 29, 2022

Tricida to Report Fourth Quarter Financial Results and Host Conference Call and Webcast on Tuesday, March 29, 2022

GlobeNewswire March 16, 2022

Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

GlobeNewswire March 2, 2022